WE SEE THE FUTURE FIRST

WE SEE THE FUTURE FIRST

Minerva Biotechnologies is focused on cancer and stem cell therapeutics. We are developing cancer immunotherapies targeting 80% of solid tumors and to prevent cancer metastasis

more info
patternframe

Welcome to Minerva Biotechnologies

Exploring the Space between Cancers and Stem Cells

Cancer Therapeutics

Cancer Therapeutics

Minerva's CAR T therapeutics will attack solid tumors that are MUC1* positive. This represents approximately 80% of all cancers.

learn more
Regenerative Medicine

Regenerative Medicine

Minerva’s stem cell discoveries will enable pharmaceutical companies to utilize regenerative medicine in a variety of diseases.

learn more
AlphaSTEM®

AlphaSTEM®

Using AlphaSTEM® iPSC generation is more efficient, cell expansion is faster, and differentiation efficiency is increased.

learn more

We See The Future First.

Minerva Biotechnologies Launches AlphaSTEM® , A Naïve Stem Cell Culture System

featured news

Minerva Biotechnologies Launches AlphaSTEM® , A Naïve Stem Cell Culture System

Minerva Biotechnologies, a leading cancer therapy and regenerative medicine company, today announced the launch of the AlphaSTEM® ...

Posted on February 14, 2017

view more DETAILS

Latest News

June 27, 2017

Now Hiring! (BS/MS) Scientist - Immunotherapy

Scientist – Immunotherapy (BS/MS) Minerva Biotechnologies is developing

June 26, 2017

Minerva CEO Speaking at Conference on Cancer Stem Cells & Regenerative Medicine

      Dr. Cynthia Bamdad, CEO and Founder of

May 30, 2017

Minerva Exhibiting at International Society for Stem Cell Research 2017

Visit us at booth # 637 The ISSCR annual meeting brings together stem cell

View All News

We See The Future First.

Sign Up For Our Mailing List.